Search - tctmd.com

Displaying 1 - 16 of 16

Sort: Relevancy | Date

News Daily News

FDA Approves Aficamten for Obstructive HCM

L.A. McKeown

December 29, 2025

News Daily News

Aprocitentan Effective in CKD Patients With Resistant Hypertension: PRECISION

Todd Neale

December 16, 2025

News Daily News

FDA Drops REMS Requirement for Antihypertensive Aprocitentan

Michael O'Riordan

April 09, 2025

SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM

Michael O'Riordan

May 13, 2024

News Daily News

New HCM Guidelines Focus on Cardiac Myosin Inhibitors and Exercise

Yael L. Maxwell

May 08, 2024

News Daily News

FDA Approves Aprocitentan for Inadequately Controlled Hypertension

Michael O'Riordan

March 20, 2024

News Daily News

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

Michael O'Riordan

April 29, 2022

News Daily News

Patient-Level Data Strengthen Rosiglitazone-CV Link: Meta-analysis

Caitlin E. Cox

February 07, 2020

News Daily News

FDA Adds Boxed Warning About CV Risks to Gout Drug Febuxostat

Shelley Wood

February 22, 2019

Febuxostat Emerges Relatively Unscathed After FDA Advisory Committee Vote

News Daily News

Febuxostat Emerges Relatively Unscathed After FDA Advisory Committee Review

Caitlin E. Cox

January 11, 2019

News Daily News

FDA Calls It Quits on Black-Box Warnings for Smoking Cessation Drugs

Shelley Wood

December 20, 2016

News Daily News

备受争议的 LIGHT 试验现已发表，但未能证实 Contrave 的心血管风险

Michael O'Riordan

March 08, 2016

News Daily News

El Controvertido Ensayo LIGHT Ahora Publicado No Arroja Luz sobre los Riesgos CV de Contrave

Michael O'Riordan

March 08, 2016

News Daily News

Controversial LIGHT Trial Now Published but Fails to Illuminate CV Risks of Contrave

Michael O'Riordan

March 08, 2016

News Industry News

FDA Approves XARELTO® (rivaroxaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation

November 04, 2011

News Industry News

FDA Approves New Medicine BRILINTA™ (Ticagrelor) for Use in the US

July 20, 2011

Advertisement

FDA Approves Aficamten for Obstructive HCM

Aprocitentan Effective in CKD Patients With Resistant Hypertension: PRECISION

FDA Drops REMS Requirement for Antihypertensive Aprocitentan

SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM

New HCM Guidelines Focus on Cardiac Myosin Inhibitors and Exercise

FDA Approves Aprocitentan for Inadequately Controlled Hypertension

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

Patient-Level Data Strengthen Rosiglitazone-CV Link: Meta-analysis

FDA Adds Boxed Warning About CV Risks to Gout Drug Febuxostat

Febuxostat Emerges Relatively Unscathed After FDA Advisory Committee Review

FDA Calls It Quits on Black-Box Warnings for Smoking Cessation Drugs

备受争议的 LIGHT 试验现已发表，但未能证实 Contrave 的心血管风险

El Controvertido Ensayo LIGHT Ahora Publicado No Arroja Luz sobre los Riesgos CV de Contrave

Controversial LIGHT Trial Now Published but Fails to Illuminate CV Risks of Contrave

FDA Approves XARELTO® (rivaroxaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation

FDA Approves New Medicine BRILINTA™ (Ticagrelor) for Use in the US

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content